Dr. Lathia has more than 30 years of experience in clinical pharmacology, translational medicine nonclinical development, and regulatory affairs at both large and small biopharma companies. He has co-led over 25 Investigational New Drug (IND) applications and 10 New Drug Applications (NDAs)/Biologics License Applications (BLAs) in the U.S and Europe. He led BioXcel Therapeutics’ regulatory strategy and development of Igalmi™ from IND to NDA approval in 3.5 years and has led the regulatory team to eight IND submissions. In addition to presenting development/regulatory strategy at meetings with drug regulators, he has made presentations to the Special Advisory Group (SAG) of the European Medicines Agency, an advisory meeting held by Taiwanese regulators, and at meetings with Chinese and Japanese regulators. Dr. Lathia has also delivered presentations to the FDA on invitation from the agency's Office of Clinical Pharmacology.

Prior to joining BioXcel Therapeutics, Dr. Lathia served as Vice President and Head of Clinical Pharmacology at Intarcia Therapeutics, where he led the pharmacokinetics (PK)/pharmacodynamics (PD), immunogenicity and bioanalytical strategy. Earlier, he served as Executive Director, Clinical Pharmacology at Alexion Pharmaceuticals, leading the global clinical and nonclinical PK/PD, pharmacometrics, and bioanalytical functions. Dr. Lathia also served as Global Head, Oncology Biomarkers and Pharmacokinetics, and as Global Clinical Pharmacology Leader for Nexavar® at Bayer. In addition, he was Senior Research Associate at Parke-Davis Research, where he was the DMPK & Clinical PK functional leader for the oncology and cardiovascular therapeutic areas. Dr. Lathia earned a doctorate in pharmacokinetics from Virginia Commonwealth University and a bachelor’s degree in pharmacy, with a gold medal in pharmacology, from L M College of Pharmacy, India.